CN106866658B - 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途 - Google Patents

1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途 Download PDF

Info

Publication number
CN106866658B
CN106866658B CN201610920720.9A CN201610920720A CN106866658B CN 106866658 B CN106866658 B CN 106866658B CN 201610920720 A CN201610920720 A CN 201610920720A CN 106866658 B CN106866658 B CN 106866658B
Authority
CN
China
Prior art keywords
pyrrolo
pyridin
pyrazole
benzyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610920720.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106866658A (zh
Inventor
斯蒂芬·斯托克斯
克里斯多佛·约翰·格雷厄姆
斯图亚特·克里斯多佛·雷
艾玛·杰妮·斯蒂芬尼亚克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Werneris R&d Co ltd
Original Assignee
Werneris R&d Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werneris R&d Co ltd filed Critical Werneris R&d Co ltd
Publication of CN106866658A publication Critical patent/CN106866658A/zh
Application granted granted Critical
Publication of CN106866658B publication Critical patent/CN106866658B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201610920720.9A 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途 Expired - Fee Related CN106866658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
GB1201566.5 2012-01-30
CN201380014717.5A CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380014717.5A Division CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Publications (2)

Publication Number Publication Date
CN106866658A CN106866658A (zh) 2017-06-20
CN106866658B true CN106866658B (zh) 2021-04-27

Family

ID=45876325

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201610920720.9A Expired - Fee Related CN106866658B (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN201610920724.7A Pending CN107011341A (zh) 2012-01-30 2013-01-30 1H‑吡咯并[2,3‑b]吡啶衍生物及它们作为激酶抑制剂的用途
CN201380014717.5A Pending CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN202010405942.3A Pending CN111484493A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201610920724.7A Pending CN107011341A (zh) 2012-01-30 2013-01-30 1H‑吡咯并[2,3‑b]吡啶衍生物及它们作为激酶抑制剂的用途
CN201380014717.5A Pending CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN202010405942.3A Pending CN111484493A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Country Status (21)

Country Link
US (3) US10000481B2 (enExample)
EP (1) EP2809670B1 (enExample)
JP (1) JP6199316B2 (enExample)
CN (4) CN106866658B (enExample)
AU (1) AU2013213954B2 (enExample)
BR (1) BR112014018795B1 (enExample)
CA (1) CA2862940C (enExample)
DK (1) DK2809670T3 (enExample)
EA (1) EA026657B1 (enExample)
ES (1) ES2637340T3 (enExample)
GB (1) GB201201566D0 (enExample)
HK (1) HK1200447A1 (enExample)
HU (1) HUE035332T2 (enExample)
IL (1) IL233595B (enExample)
IN (1) IN2014DN06104A (enExample)
MX (1) MX352927B (enExample)
NZ (1) NZ627361A (enExample)
PL (1) PL2809670T3 (enExample)
PT (1) PT2809670T (enExample)
WO (1) WO2013114113A1 (enExample)
ZA (1) ZA201405070B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
CA2871436C (en) * 2012-04-23 2020-07-28 Genentech, Inc. Intermediates and processes for preparing compounds for use as chk1 inhibitors
EP3036227B1 (en) * 2013-08-22 2020-01-08 Genentech, Inc. Process for preparing a compound
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
IL261107B2 (en) 2016-02-23 2023-11-01 Taiho Pharmaceutical Co Ltd A novel compressed pyrimidine compound or a salt thereof
MY201941A (en) 2017-08-21 2024-03-25 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
US12428395B2 (en) 2019-08-01 2025-09-30 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
EP4182030A1 (en) * 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
PE20240931A1 (es) 2021-08-10 2024-04-30 Ifm Due Inc Compuestos y composiciones para tratar condiciones asociadas con actividad de sting
WO2023137034A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887A (zh) * 2008-01-08 2011-01-26 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102089307A (zh) * 2008-05-13 2011-06-08 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102119162A (zh) * 2008-06-11 2011-07-06 健泰科生物技术公司 二氮杂咔唑及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1684694A2 (en) * 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
ES2433230T3 (es) * 2009-08-06 2013-12-10 Merck Patent Gmbh Compuestos bicíclicos novedosos de urea
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887A (zh) * 2008-01-08 2011-01-26 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102089307A (zh) * 2008-05-13 2011-06-08 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102119162A (zh) * 2008-06-11 2011-07-06 健泰科生物技术公司 二氮杂咔唑及其使用方法

Also Published As

Publication number Publication date
EP2809670A1 (en) 2014-12-10
CN107011341A (zh) 2017-08-04
BR112014018795B1 (pt) 2020-09-29
US20150011533A1 (en) 2015-01-08
IL233595B (en) 2018-05-31
BR112014018795A2 (pt) 2017-07-04
CN106866658A (zh) 2017-06-20
NZ627361A (en) 2016-07-29
EA026657B1 (ru) 2017-05-31
EA201491376A1 (ru) 2015-01-30
DK2809670T3 (en) 2017-08-28
AU2013213954A1 (en) 2014-08-07
CN104203948A (zh) 2014-12-10
AU2013213954B2 (en) 2016-02-25
PT2809670T (pt) 2017-08-23
HUE035332T2 (en) 2018-05-02
US20180362526A1 (en) 2018-12-20
ES2637340T3 (es) 2017-10-11
CA2862940C (en) 2021-09-14
CN111484493A (zh) 2020-08-04
JP6199316B2 (ja) 2017-09-20
CA2862940A1 (en) 2013-08-08
MX352927B (es) 2017-12-14
EP2809670B1 (en) 2017-05-17
WO2013114113A1 (en) 2013-08-08
HK1200447A1 (en) 2015-08-07
ZA201405070B (en) 2016-03-30
US10000481B2 (en) 2018-06-19
US10889582B2 (en) 2021-01-12
IN2014DN06104A (enExample) 2015-08-14
IL233595A0 (en) 2014-08-31
MX2014009112A (es) 2014-11-10
GB201201566D0 (en) 2012-03-14
JP2015505555A (ja) 2015-02-23
US20210206762A1 (en) 2021-07-08
PL2809670T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
CN106866658B (zh) 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
JP7317878B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
US20250127903A1 (en) Substituted piperidine degronimers for target protein degradation
CN113453679B (zh) 靶向蛋白降解
CN109970743B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
CN110088096A (zh) 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物
CN108473478A (zh) TBK/IKKε抑制剂化合物及其用途
US20240158370A1 (en) CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240227A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240217A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240217B (zh) 1h-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
HK40010369A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK40010369B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
HK40063935A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
HK1233621A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK1228897B (zh) 用作btk抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240217

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210427